Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in ...

This important study provides evidence for dynamic coupling between translation initiation and elongation that can help maintain low ribosome density and translational homeostasis. The authors combine ...

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna (Nasdaq: MRNA) and BioNTech (Nasdaq: BNTX) generating momentum and sharpening ...

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have found a way to do just that—by tweaking a key molecule in the vaccine’s ...

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are devastating and incurable diseases.

NIIMBL had selected projects that are most likely to help overcome common production hurdles.

Moderna, Inc. (NASDAQ:MRNA) today announced business and clinical updates across its franchises and introduced several new development programs at the Company's annual R&D Day.

“tRNA molecules can be cleaved into small but stable RNA fragments which circulate in blood plasma. These molecules are typically altered in cancer patients, and are hugely information-rich for ...

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The collaboration, under a sponsored research ...

Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?